Themis Medicare Limited (TML) a Pharmaceutical Company established in collaboration with Gedeon Richter Ltd., of Hungary , is engaged in the manufacturing and marketing of API, Bulk intermediates and Formulations of synthetic and fermentation origin.

Themis Medicare is also actively involved in research activity, which has led to the development of several first-of-their-kind molecules in the world as well as products under NDDS. Activity in such areas also encompasses clinical investigation, registration & patenting of the new developments.

Our breakthrough molecules are-

• α, β - Arteether - an original 3 rd generation artemisinin derivative
   

• Feracrylum – a unique haemostatic hygroscopic agent
   

• Centbucridine – a safer, more efficacious, and longer acting local anaesthetic agent

While our products under NDDS – first ever of their kind in the world are-

• Rofecoxib I. M. Injection
   

• Nimesulide I. M. Injection
   

• Aceclofenac I. M. Injection
   

• Etoricoxib I. M. Injection
   

• Lipid free Propofol I. V. Injection
   

• Terbinafine topical formulations (Clear gel & Lacquer)